Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01408355 | A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose. | PHASE1 | COMPLETED | 5 | — | — | Jul 1, 2011 | Aug 1, 2011 | Sep 9, 2011 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| 50 microgram PF-06273588 intravenous | EXPERIMENTAL | Subjects will receive a single intravenous microdose of PF-06273588 in period one |
| 50 microgram PF-06273588 oral | EXPERIMENTAL | Subjects will receive a single oral microdose of PF-06273588 in period two |
| Name | Type | Description |
|---|---|---|
| PF-06273588 | DRUG | Intravenous, 50 microgram, single dose |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical...